<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3402">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062618</url>
  </required_header>
  <id_info>
    <org_study_id>PRCL-SMAD</org_study_id>
    <nct_id>NCT03062618</nct_id>
  </id_info>
  <brief_title>A Study of PRCL-02 in Healthy Volunteers and Plaque Psoriasis</brief_title>
  <official_title>Randomized, Double Blind, Placebo Controlled, Incomplete Crossover Single Oral Dose Escalation of PRCL-02 in Normal Healthy Volunteers (Part A) and Multiple Oral Dose Escalation in Normal Healthy Volunteers (Part B) and in Chronic Plaque Psoriasis Patients (Part C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PRCL Research Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PRCL Research Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of three parts: single oral dose escalation in healthy volunteers (Part
      A), and multiple oral dose escalations in healthy volunteers (Part B) and in participants
      with chronic plaque psoriasis (Part C)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2017</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Events (Part A)</measure>
    <time_frame>Baseline up to approximately 10 days post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Events (Part B)</measure>
    <time_frame>Baseline up to approximately 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Events (Part C)</measure>
    <time_frame>Baseline up to approximately 5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Triplicate 12-lead Electrocardiogram (ECG) in Part A</measure>
    <time_frame>Baseline up to 24 hours post-dose on day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline in Triplicate 12-lead ECG in Part B</measure>
    <time_frame>Baseline up to 24 hours post-dose on day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline in Triplicate 12-lead ECG in Part C</measure>
    <time_frame>Baseline up to approximately day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Single 12-Lead ECG in Part A</measure>
    <time_frame>Baseline up to approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Single 12-Lead ECG in Part B</measure>
    <time_frame>Baseline up to approximately 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Single 12-Lead ECG in Part C</measure>
    <time_frame>Baseline up to approximately 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Vital Signs in Part A</measure>
    <time_frame>Baseline up to approximately 10 days</time_frame>
    <description>Respiration Rate, Heart Rate, Blood Pressure, Temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Vital Signs in Part B</measure>
    <time_frame>Baseline up to approximately 2 weeks</time_frame>
    <description>Respiration Rate, Heart Rate, Blood Pressure, Temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Vital Signs in Part C</measure>
    <time_frame>Baseline up to approximately 5 weeks</time_frame>
    <description>Respiration Rate, Heart Rate, Blood Pressure, Temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Physical Examination Findings in Part A</measure>
    <time_frame>Baseline up to approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Physical Examination Findings in Part B</measure>
    <time_frame>Baseline up to approximately 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Physical Examination Findings in Part C</measure>
    <time_frame>Baseline up to approximately 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Laboratory Test Results outside of reference range in Part A</measure>
    <time_frame>Baseline up to approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Laboratory Test Results outside of reference range in Part B</measure>
    <time_frame>Baseline up to approximately 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Laboratory Test Results outside of reference range in Part C</measure>
    <time_frame>Baseline up to approximately 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) in Part A</measure>
    <time_frame>Baseline up to 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) in Part B</measure>
    <time_frame>Baseline up to approximately Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) in Part C</measure>
    <time_frame>Baseline up to approximately Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Drug Concentration (Tmax) in Part A</measure>
    <time_frame>Baseline up to 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Drug Concentration (Tmax) in Part B</measure>
    <time_frame>Baseline up to approximately Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Drug Concentration (Tmax) in Part C</measure>
    <time_frame>Baseline up to approximately on Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity (AUC0-âˆž) in Part A</measure>
    <time_frame>Baseline up to 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Plasma Concentration-Time Curve During the Dosing Interval (24h) (AUC0-tau) in Part B</measure>
    <time_frame>Baseline up to approximately Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Plasma Concentration-Time Curve During the Dosing Interval (24h) (AUC0-tau) in Part C</measure>
    <time_frame>Baseline up to approximately Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum or Trough Concentration (Cmin)</measure>
    <time_frame>Predose up to 72 hours post-dose (Part A), Day 8 (Part B), Day 31 (Part C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lag Time: Time Delay Between Drug Administration and First Observed Plasma Concentration (Tlag)</measure>
    <time_frame>Predose up to 72 hours post-dose (Part A), Day 8 (Part B), Day 31 (Part C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate (Ke)</measure>
    <time_frame>Predose up to 72 hours post-dose (Part A), Day 8 (Part B), Day 31 (Part C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2)</measure>
    <time_frame>Predose up to 72 hours post-dose (Part A), Day 8 (Part B), Day 31 (Part C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve from Time Zero to 24 Hours Post-dose (AUC0-24)</measure>
    <time_frame>Predose up to 72 hours post-dose (Part A), Day 8 (Part B), Day 31 (Part C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve from Time Zero to the Last Observed Time Point (AUC0-t)</measure>
    <time_frame>Predose up to 72 hours post-dose (Part A), Day 8 (Part B), Day 31 (Part C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F)</measure>
    <time_frame>Predose up to 72 hours post-dose (Part A), Day 8 (Part B), Day 31 (Part C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F)</measure>
    <time_frame>Predose up to 72 hours post-dose (Part A), Day 8 (Part B), Day 31 (Part C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio</measure>
    <time_frame>Predose up to 72 hours post-dose (Part A), Day 8 (Part B), Day 31 (Part C)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Part A: Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two escalating sequences of single oral doses of PRCL-02, in 3 periods, starting at 4 milligrams (mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Single Dose (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two escalating sequences of matching placebo oral tablets, in 3 periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Multiple Dose (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple oral doses of placebo for 28 days, at matching dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Multiple Dose (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple oral doses of placebo for 28 days, at matching dose levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRCL-02</intervention_name>
    <description>Oral tablet(s) administered with water</description>
    <arm_group_label>Part A: Single Dose</arm_group_label>
    <arm_group_label>Part B: Multiple Dose</arm_group_label>
    <arm_group_label>Part C: Multiple Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Administered with water</description>
    <arm_group_label>Part A: Single Dose (Placebo)</arm_group_label>
    <arm_group_label>Part B: Multiple Dose (Placebo)</arm_group_label>
    <arm_group_label>Part C: Multiple Dose (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Parts A and B

          -  Be 18 to 55 years old

          -  Be healthy with absence of clinically significant illness

          -  Male participants must agree to use medically accepted methods of contraception with
             all sexual partners during the study, and for 90 days after

          -  Female participants must be postmenopausal or surgically sterile

          -  Have venous access sufficient for blood sampling

          -  Be a non-smoker

        Part C

          -  Be 18 to 65 years old

          -  Have chronic plaque psoriasis based on a confirmed diagnosis of plaques for at least
             6 months

          -  Have at least 4 evaluable plaques located in at least 2 body regions

        Exclusion Criteria:

        Parts A and B

          -  Significant abnormalities in vital signs, laboratory tests, electrocardiogram, or
             history of heart disease, some allergies, or infections

          -  Hepatic or renal impairment

          -  Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV)

          -  Female participants who are pregnant or breast feeding

          -  Recent or ongoing infection

          -  History of alcohol or drug abuse

          -  Current or recent enrollment in a clinical trial judged not compatible with this
             study

        Part C

          -  Have highly active psoriatic arthritis

          -  Have pustular, erythrodermic and/or guttate forms of psoriasis

          -  Have had a clinically-significant flare of psoriasis during the last 12 weeks

          -  Currently or recently taking certain prescribed therapies for psoriasis

          -  Use of selected topical treatments within 4 weeks prior to starting the study (use of
             some emollients without urea is allowed, except on one lesion for biopsy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email PRCL@Choruspharma.com</last_name>
    <role>Study Director</role>
    <affiliation>PRCL Research Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>InVentiv Health</name>
      <address>
        <city>Quebec</city>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Larouche</last_name>
      <phone>866-262-7427</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 20, 2017</lastchanged_date>
  <firstreceived_date>February 20, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
